Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Vanuatu Health Times.
Press releases published on September 29, 2025
Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
CAN-2409 improved disease-free survival in patients with intermediate-to-high-risk, localized prostate cancer compared to placebo in patients treated with either conventional or moderate hypofractionated radiotherapy with curative intent, independent of …
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Re-Files Abbreviated New Drug Application (ANDA) for KETAFREE™, Preservative-Free IV Ketamine
KETAFREE™ to provide innovative, preservative-free IV ketamine formulation, eliminating toxic preservatives, in keeping with current HHS priorities to eliminate toxic preservatives from foods and drugs Filing is based on FDA interaction and approval of …
Cosmos Health CEO Issues Letter to Shareholders: Building a Global Healthcare Powerhouse with $300M Digital Financing Facility, U.S. Manufacturing Expansion, and AI Innovation
CHICAGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its Chief Executive Officer, Greg Siokas, has issued the …
Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma
Study will evaluate ELI-002 7P in combination with chemotherapy and a checkpoint inhibitor (“CPI”) in the neoadjuvant setting Trial is anticipated to begin enrolling in H1’2026 BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: …
Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial
Results to be presented at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions BASKING RIDGE, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: …
Neura Health Secures $11.4 Million Series A to Fuel National Expansion of Comprehensive, Tech-Enabled Neurology Care Model
Funding marks first-ever investment by the American Heart Association’s Go Red for Women Venture Fund™ Comes on the heels of Neura’s expansion into memory care, addressing a critical shortage in cognitive neurologists amid the growing ‘Silver Tsunami’ NEW …
Apyx Medical to Host Virtual Key Opinion Leader Event to Discuss the Commercial Launch of The AYON Body Contouring System™ on October 14, 2025
CLEARWATER, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion® and the AYON Body …
The Oncology Institute Partners with Protocol Behavioral Health to Integrate Mental Health Services into Cancer Care
CERRITOS, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute (NASDAQ: TOI), a pioneer in value-based community oncology care, is pleased to announce a new partnership with Protocol Behavioral Health, a leading provider of evidence-based …
MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum
CARMEL, Ind., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic …
electroCore Announces Reimbursement Approval for gammaCore™ by RIZIV/INAMI in Belgium
ROCKAWAY, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that gammaCore™ Sapphire (nVNS) has been included in a long-term reimbursement policy …
Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus
– Patent covers esophagus produced using Humacyte’s proprietary bioengineered regenerative tissue platform, designed for implant in patients with damaged esophagus – – Patent provides coverage into 2041 for the composition of novel bioengineered esophagus …
Reflect Scientific Secures Over $1 Million in Follow-On Orders for B-90 Blast Freezer
OREM, Utah, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a provider of advanced cryogenic cooling solutions, today announced it has received follow-on orders totaling more than $1 million for its B-90 blast freezer. This …
Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston
SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic …
Hyperion DeFi Announces Appointment of David Knox as Chief Financial Officer
PayPal’s Former Head of Capital Markets and Head of Finance for Global Credit and Financial Services Joins Company Strong Advocate for Blockchain Adoption for Traditional Institutional Financial Products LAGUNA HILLS, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE …
Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer
KNOXVILLE, Tenn., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the start of a preclinical study of its lead investigational drug PV-10 in an orthotopic bladder cancer …
MindRank Announces Positive 12-week Once-Daily (QD) Results for AI-Designed Oral GLP-1 Agonist MDR-001 in Adults with Obesity
HANGZHOU, China and LONDON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- MindRank AI Ltd., a clinical-stage artificial intelligence (AI)-empowered drug discovery company, today announced the positive topline results of its oral small-molecule GLP-1 receptor agonist …
Halberd Corporation Acquires NeuroSense AI Corp., a Revolutionary Behavioral Intelligence Platform to Transform TBI, Other Research, and Clinical Assessment
JACKSON CENTER, Pa., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC: HALB) today announced its acquisition of NeuroSense AI Corp., a groundbreaking artificial intelligence platform that will revolutionize behavioral analysis for traumatic …
INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer’s Disease to npj Dementia, a Nature Portfolio Journal
Boca Raton, FL, Sept. 29, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces the submission of a manuscript detailing the results of its Phase 2 MINDFuL trial. The manuscript, …
KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint
-- Study did not meet primary endpoint of complete healing of PCED at Week 8; secondary endpoints also did not achieve statistical significance -- -- KPI-012 was well-tolerated with no treatment-related serious adverse events observed -- -- KALA to cease …
Cytokinetics Presents New Data Related to Aficamten at the HFSA Annual Scientific Meeting 2025
Additional Data from MAPLE-HCM Show Aficamten Significantly Improves Measures of Maximal and Submaximal Exercise Capacity and Recovery Compared to Metoprolol 96-Week Analyses from FOREST-HCM Support Long-Term Efficacy and Tolerability of Aficamten in …